


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:


1. (currently amended) ~~Substituted 9a-N {N' [4-(sulfonyl)phenylcarbamoyl]}~~  
~~derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and 5-O-~~  
~~desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A~~ A compound of  
the general formula 1,



1


- wherein R represents H or cladineryl moiety, and R<sup>1</sup> represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino or 5-methyl-3-isoxazolylamino group, or a pharmaceutically acceptable salt thereof.
2. (currently amended) A substance compound according to claim 1, characterized in that R<sup>1</sup> represents chloro group and R represents cladineryl moiety.
  3. (currently amended) A substance compound according to claim 1 characterized in that R<sup>1</sup> represents chloro group, and R represents H.
  4. (currently amended) A compound ~~Substance~~ according to claim 1 where R<sup>1</sup> represents amino group, and R represents cladineryl moiety.

5. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R<sup>1</sup> represents phenylamino group, and R represents cladinosyl group.
6. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R<sup>1</sup> represents 2-pyridylamino group, and R represents cladinosyl group.
7. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R<sup>1</sup> represents 3,4-dimethyl-5-isoxazolyl group, and R represents cladinosyl moiety.
8. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R<sup>1</sup> represents 5-methyl-3-isoxazolylamino group, and R represents cladinosyl group.
9. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R<sup>1</sup> represents amino group and R represents H.
10. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R<sup>1</sup> represents phenylamino group, and R represents H.
11. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R<sup>1</sup> represents 2-pyridylamino group, and R represents H.
12. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R<sup>1</sup> represents 3,4-dimethyl-5-isoxazolylamino group, and R represents H.
13. (currently amended) A ~~substance~~ compound according to claim 1, characterized in that R<sup>1</sup> represents 5-methyl-3-isoxazolylamino group and R represents H.
14. (currently amended) A process for the preparation of ~~substituted 9a-N-(N'-(4-(sulfonyl)phenyl carbamoyl)) derivatives of 9-deoxo-9-dihydro-9a-aza-9a-hemoerythromycin A and 5-O-decosaminyl-9-deoxo-9-dihydro-9a-aza-9a-hemoerythronolide A~~ a compound of the general formula 1,




1

wherein R<sup>1</sup> represents amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino or 5-methyl-3-isoxazolylamino group and R represents H or cladinosyl group, comprising reacting ~~9-deoxy-9-dihydro-9a-aza-9a-hemoerythromycin A or 5-O-desosaminyl-9-deoxy-9-dihydro-9a-aza-9a-hemoerythronolide A~~ a compound of general formula 2




2

wherein R represents H or cladinosyl group, with 4-(chlorosulfonyl)phenyl isocyanate formula 3,



3


to form a compound of formula 1 wherein R is H or cladinosyl group and R<sup>1</sup> is chloro; reacting a compound of formula 1 wherein R is H or cladinosyl group and R<sup>1</sup> is chloro with ammonia or amine of general formula 4,



4


wherein R<sup>2</sup> represents H, phenyl, 2-pyridyl, 3,4-dimethyl-5-isoxazolyl or 5-methyl-3-isoxazolyl group, in toluene, xylene or some other aprotic solvent, at a temperature 0-110°C to form a compound of formula 1 wherein R is H or cladinosyl and R<sup>1</sup> is amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino or 5-methyl-3-isoxazolylamino.

15. (original) Pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibacterially effective amount of the substances according to claim 1.
16. cancelled
17. (previously presented) A method for inhibiting bacterial growth in vitro on a surface or in a substance comprising applying to said surface or substance a bactericially effective amount of a compound according to claim 1.
18. (previously presented) The method of claim 17 wherein the surface is selected from the group consisting of a wall, a room, and a medical instrument.
19. (previously presented) The method of claim 17 wherein the substance is selected from the group of wall coatings and wooden coatings.
20. (currently amended) A process for the preparation of substituted 9a-N-(N'-(4-(sulfonyl)phenyl carbamoyl)) derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A a compound of the general formula 1,




1

wherein R<sup>1</sup> represents chloro and R represents H or cladinosyl group, comprising reacting ~~9-deoxy-9-dihydro-9a-aza-9a-homocorythromycin A or 5-O-desosaminyl-9-deoxy-9-dihydro-9a-aza-9a-homocorythronolide A~~ a compound of general formula 2



2


wherein R represents H or cladinosyl group with 4-(chlorosulfonyl)phenyl isocyanate formula 3,



3

to form a compound of formula 1 wherein R is H or cladinosyl and R<sup>1</sup> is chloro.

21. (currently amended) ~~A compound Substituted 9a-N{N'[4-~~  
~~(sulfonyl)phenylcarbamoyl]] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-~~  
~~homoerythromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-~~  
~~homoerythronolide A of the general formula 1,~~



1

wherein R represents H or cladineryl moiety, and R<sup>1</sup> represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino or 5-methyl-3-isoxazolylamino group.